Objectives: Nearly 1 in 3 cancer patients undergoing radiotherapy experience anxiety, which can negatively affect both quality of life and prognosis. This systematic review aimed to synthesize evidence on patient education and its impact on anxiety levels among cancer patients undergoing radiotherapy. Methods: We conducted a systematic review of the current literature using 3 scientific databases—PubMed, EBSCOhost, and Web of Science—to identify intervention studies. Data were analyzed using a narrative synthesis approach, integrating findings across studies to draw comprehensive conclusions. Results: Fifteen studies involving 1988 participants were included. Baseline anxiety levels, measured using various instruments, ranged from 2.9% to 88.2% before radiotherapy and declined thereafter in both intervention and control groups. Most studies reported no significant difference in anxiety reduction between intervention groups receiving educational programs and control groups receiving standard education. However, interventions that were more intensive and delivered by professional staff were more likely to produce statistically significant reductions in anxiety. Conclusions This review suggests that patient education remains relevant for reducing anxiety among cancer patients undergoing radiotherapy. Routine screening for anxiety prior to radiotherapy is recommended, along with the development of more intensive and tailored educational interventions rather than passive or minimal approaches.

Purpose: This study investigates natrium iodide symporter (NIS) expression in three breast cancer subtypes to predict radioiodine response. Materials and Methods: Frozen breast tissues from triple negative (TN), human epidermal receptor 2 (HER2+), and luminal A cancers were used in this research. NIS protein expression in each subtype was analyzed using immunohistochemistry (IHC) and western blot (WB). Secondary data such as age, subtypes, and Ki 67 index were drawn from the surgical oncologist database. Breast cancer cell lines were used to investigate the effect of radioiodine by measuring cell proliferation. Results: The forty-one breast cancer samples were analyzed consisted of the following subtypes: TN, HER2+, and luminal A were 58%, 22%, and 20% respectively. The stages of disease were 2A to 4A. Most of samples were at 3B. Ki 67 index of TN, HER2+, and luminal A were 21 ± 12, 19 ± 5, and 7 ± 3 respectively. The NIS expression was detected in 95% of samples in cytoplasm and/or cell membrane; 93% of samples were invasive breast carcinomas. Only 20% of the samples showed NIS expression at cell membrane; four samples were HER2+, and other four were TN subtypes. NIS membrane score was significantly positively correlated with Ki67 index, p = 0.04. NIS protein expression was detected at sizes 88 kDa, 50 kDa, and 27 kDa. Cell proliferation rate means of MDA-MB 231, SKBR3, and MCF7 cells were 81.6 ± 4, 10.6 ± 5, and 15.4 ± 13 respectively (p = 0.009). Conclusion NIS protein expression is detectable in breast cancer cells to varying degrees. HER2+ is the most likely to express NIS in the cell membrane followed by TN subtypes. This indicates that radioiodine could be used as a novel adjuvant treatment in breast cancer.